December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This paper identifies Galeal Tension-Induced Follicular Hypoxia as a mechanism for male pattern baldness, proposing a new therapeutic protocol targeting underlying physiological failures rather than just symptoms.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This study elucidates a mechanism for male pattern baldness involving chronic scalp tension leading to follicular hypoxia, rather than purely hormonal factors, and proposes a treatment targeting electrolyte, vascular, and neurological factors to restore balance.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This study elucidates a mechanism for male pattern baldness involving tension in scalp muscles that leads to reduced blood flow and hypoxia around hair follicles, proposing a multi-targeted therapeutic approach.
June 2023 in “BMC Pharmacology and Toxicology” This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.
7 citations
,
August 2020 in “Journal of The American Academy of Dermatology” This letter comments on a randomized controlled trial by Shapiro et al that found no significant benefits of platelet-rich plasma compared to placebo for male androgenetic alopecia, highlighting issues with PRP protocol variations.